American Association for Cancer Research
ccr-23-1427_supplementary_table_s4_suppts4.pdf (193.85 kB)

Supplementary Table S4 from A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells

Download (193.85 kB)
journal contribution
posted on 2023-12-15, 08:40 authored by Veronica Calvo, Wei Zheng, Anna Adam-Artigues, Kirk A. Staschke, Xin Huang, Julie F. Cheung, Ana Rita Nobre, Sho Fujisawa, David Liu, Maria Fumagalli, David Surguladze, Michael E. Stokes, Ari Nowacek, Mark Mulvihill, Eduardo F. Farias, Julio A. Aguirre-Ghiso

Supplementary Table 4: KINOMEscan™ Selectivity Score for HC4, HC19, HC28 and GSK157 at concentrations of 0.1, 1.0 and 10 mM across 468 Kinases


Ramon Areces Foundation

National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...

Congressionally Directed Medical Research Programs (CDMRP)



The integrated stress response (ISR) kinase PERK serves as a survival factor for both proliferative and dormant cancer cells. We aim to validate PERK inhibition as a new strategy to specifically eliminate solitary disseminated cancer cells (DCC) in secondary sites that eventually reawake and originate metastasis. A novel clinical-grade PERK inhibitor (HC4) was tested in mouse syngeneic and PDX models that present quiescent/dormant DCCs or growth-arrested cancer cells in micro-metastatic lesions that upregulate ISR. HC4 significantly blocks metastasis, by killing quiescent/slow-cycling ISRhigh, but not proliferative ISRlow DCCs. HC4 blocked expansion of established micro-metastasis that contained ISRhigh slow-cycling cells. Single-cell gene expression profiling and imaging revealed that a significant proportion of solitary DCCs in lungs were indeed dormant and displayed an unresolved ER stress as revealed by high expression of a PERK-regulated signature. In human breast cancer metastasis biopsies, GADD34 expression (PERK-regulated gene) and quiescence were positively correlated. HC4 effectively eradicated dormant bone marrow DCCs, which usually persist after rounds of therapies. Importantly, treatment with CDK4/6 inhibitors (to force a quiescent state) followed by HC4 further reduced metastatic burden. In HNSCC and HER2+ cancers HC4 caused cell death in dormant DCCs. In HER2+ tumors, PERK inhibition caused killing by reducing HER2 activity because of sub-optimal HER2 trafficking and phosphorylation in response to EGF. Our data identify PERK as a unique vulnerability in quiescent or slow-cycling ISRhigh DCCs. The use of PERK inhibitors may allow targeting of pre-existing or therapy-induced growth arrested “persister” cells that escape anti-proliferative therapies.

Usage metrics

    Clinical Cancer Research



    Ref. manager